OBJECTIVE: To report the design and implementation of the Right Drug, Right Dose, Right Time-Using Genomic Data to Individualize Treatment protocol that was developed to test the concept that prescribers can deliver genome-guided therapy at the point of care by using preemptive pharmacogenomics (PGx) data and clinical decision support (CDS) integrated into the electronic medical record (EMR). PATIENTS AND METHODS: We used a multivariate prediction model to identify patients with a high risk of initiating statin therapy within 3 years. The model was used to target a study cohort most likely to benefit from preemptive PGx testing among the Mayo Clinic Biobank participants, with a recruitment goal of 1000 patients. We used a Cox proportional hazards model with variables selected through the Lasso shrinkage method. An operational CDS model was adapted to implement PGx rules within the EMR. RESULTS: The prediction model included age, sex, race, and 6 chronic diseases categorized by the Clinical Classifications Software for International Classification of Diseases, Ninth Revision codes (dyslipidemia, diabetes, peripheral atherosclerosis, disease of the blood-forming organs, coronary atherosclerosis and other heart diseases, and hypertension). Of the 2000 Biobank participants invited, 1013 (51%) provided blood samples, 256 (13%) declined participation, 555 (28%) did not respond, and 176 (9%) consented but did not provide a blood sample within the recruitment window (October 4, 2012, through March 20, 2013). Preemptive PGx testing included CYP2D6 genotyping and targeted sequencing of 84 PGx genes. Synchronous real-time CDS was integrated into the EMR and flagged potential patient-specific drug-gene interactions and provided therapeutic guidance. CONCLUSION: This translational project provides an opportunity to begin to evaluate the impact of preemptive sequencing and EMR-driven genome-guided therapy. These interventions will improve understanding and implementation of genomic data in clinical practice.
OBJECTIVE: To report the design and implementation of the Right Drug, Right Dose, Right Time-Using Genomic Data to Individualize Treatment protocol that was developed to test the concept that prescribers can deliver genome-guided therapy at the point of care by using preemptive pharmacogenomics (PGx) data and clinical decision support (CDS) integrated into the electronic medical record (EMR). PATIENTS AND METHODS: We used a multivariate prediction model to identify patients with a high risk of initiating statin therapy within 3 years. The model was used to target a study cohort most likely to benefit from preemptive PGx testing among the Mayo Clinic Biobank participants, with a recruitment goal of 1000 patients. We used a Cox proportional hazards model with variables selected through the Lasso shrinkage method. An operational CDS model was adapted to implement PGx rules within the EMR. RESULTS: The prediction model included age, sex, race, and 6 chronic diseases categorized by the Clinical Classifications Software for International Classification of Diseases, Ninth Revision codes (dyslipidemia, diabetes, peripheral atherosclerosis, disease of the blood-forming organs, coronary atherosclerosis and other heart diseases, and hypertension). Of the 2000 Biobank participants invited, 1013 (51%) provided blood samples, 256 (13%) declined participation, 555 (28%) did not respond, and 176 (9%) consented but did not provide a blood sample within the recruitment window (October 4, 2012, through March 20, 2013). Preemptive PGx testing included CYP2D6 genotyping and targeted sequencing of 84 PGx genes. Synchronous real-time CDS was integrated into the EMR and flagged potential patient-specific drug-gene interactions and provided therapeutic guidance. CONCLUSION: This translational project provides an opportunity to begin to evaluate the impact of preemptive sequencing and EMR-driven genome-guided therapy. These interventions will improve understanding and implementation of genomic data in clinical practice.
Keywords:
CAB; CAP; CDS; CGSL; CLIA; Clinical Genome Sequencing Laboratory; Clinical Laboratory Improvement Amendments; College of American Pathologists; Community Advisory Board; EMR; Electronic Medical Record and Genomics; FDA; Food and Drug Administration; NGS; PGL; PGRN; PGx; Personalized Genomics Laboratory; Pharmacogenomics Research Network; RIGHT; The Right Drug, Right Dose, Right Time—Using Genomic Data to Individualize Treatment; clinical decision support; eMERGE; electronic medical record; next-generation sequencing; pharmacogenomics
Authors: Janet E Olson; Euijung Ryu; Kiley J Johnson; Barbara A Koenig; Karen J Maschke; Jody A Morrisette; Mark Liebow; Paul Y Takahashi; Zachary S Fredericksen; Ruchi G Sharma; Kari S Anderson; Matthew A Hathcock; Jason A Carnahan; Jyotishman Pathak; Noralane M Lindor; Timothy J Beebe; Stephen N Thibodeau; James R Cerhan Journal: Mayo Clin Proc Date: 2013-09 Impact factor: 7.616
Authors: R A Wilke; L B Ramsey; S G Johnson; W D Maxwell; H L McLeod; D Voora; R M Krauss; D M Roden; Q Feng; R M Cooper-Dehoff; L Gong; T E Klein; M Wadelius; M Niemi Journal: Clin Pharmacol Ther Date: 2012-05-23 Impact factor: 6.875
Authors: Abel N Kho; Jennifer A Pacheco; Peggy L Peissig; Luke Rasmussen; Katherine M Newton; Noah Weston; Paul K Crane; Jyotishman Pathak; Christopher G Chute; Suzette J Bielinski; Iftikhar J Kullo; Rongling Li; Teri A Manolio; Rex L Chisholm; Joshua C Denny Journal: Sci Transl Med Date: 2011-04-20 Impact factor: 17.956
Authors: Walter A Rocca; Barbara P Yawn; Jennifer L St Sauver; Brandon R Grossardt; L Joseph Melton Journal: Mayo Clin Proc Date: 2012-11-28 Impact factor: 7.616
Authors: Maya S Safarova; Eric W Klee; Linnea M Baudhuin; Erin M Winkler; Michelle L Kluge; Suzette J Bielinski; Janet E Olson; Iftikhar J Kullo Journal: Eur J Hum Genet Date: 2017-02-01 Impact factor: 4.246
Authors: John Valgus; Kristin W Weitzel; Josh F Peterson; Daniel J Crona; Christine M Formea Journal: Am J Health Syst Pharm Date: 2019-04-08 Impact factor: 2.637
Authors: Amy L Kaufman; Jared Spitz; Michael Jacobs; Matthew Sorrentino; Shennin Yuen; Keith Danahey; Donald Saner; Teri E Klein; Russ B Altman; Mark J Ratain; Peter H O'Donnell Journal: Mayo Clin Proc Date: 2015-06 Impact factor: 7.616
Authors: Brian H Shirts; Joseph S Salama; Samuel J Aronson; Wendy K Chung; Stacy W Gray; Lucia A Hindorff; Gail P Jarvik; Sharon E Plon; Elena M Stoffel; Peter Z Tarczy-Hornoch; Eliezer M Van Allen; Karen E Weck; Christopher G Chute; Robert R Freimuth; Robert W Grundmeier; Andrea L Hartzler; Rongling Li; Peggy L Peissig; Josh F Peterson; Luke V Rasmussen; Justin B Starren; Marc S Williams; Casey L Overby Journal: J Am Med Inform Assoc Date: 2015-07-03 Impact factor: 4.497
Authors: James E Kimpton; Iain M Carey; Christopher J D Threapleton; Alexandra Robinson; Tess Harris; Derek G Cook; Stephen DeWilde; Emma H Baker Journal: Br J Clin Pharmacol Date: 2019-12-13 Impact factor: 4.335
Authors: Elizabeth M Cutting; Casey L Overby; Meghan Banchero; Toni Pollin; Mark Kelemen; Alan R Shuldiner; Amber L Beitelshees Journal: AMIA Annu Symp Proc Date: 2015-11-05